← Back to Clinical Trials
Recruiting NCT06124508

NCT06124508 PromotinG Lung Cancer screenIng Awareness and Implementation in Hispanics/Latinx Head and Neck canceR Survivors

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06124508
Status Recruiting
Phase
Sponsor University of Miami
Condition Head and Neck Cancer
Study Type INTERVENTIONAL
Enrollment 44 participants
Start Date 2024-04-11
Primary Completion 2029-04-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 80 Years
Study Type INTERVENTIONAL
Interventions
Lung Cancer Screening EducationSemi-Structured InterviewStandard of Care Lung Cancer Screening Program

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 44 participants in total. It began in 2024-04-11 with a primary completion date of 2029-04-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this study is to assess the awareness of eligibility of lung cancer screening in Hispanic/LatinX Head and Neck Cancer (HNC) survivors using a survey questionnaire; and to understand the barriers to screening using qualitative interviews.

Eligibility Criteria

Inclusion Criteria: * Participants must be able to understand, and sign informed consent form. * Age ≥ 18 years. * Participants must self-identify as Hispanic/LatinX. * Individuals must be head and neck cancer survivors (treated locally with surgery, radiation alone, or definitive chemoradiation ≥ 5 years earlier and have no signs/symptoms to suggest recurrence of disease). * Subjects that meet lung cancer (LC) screening eligibility according to United States Preventive Services Task Force (USPSTF21) and/or National Comprehensive Cancer Network (NCCN). For patients with a history of head and neck cancers, the NCCN recommends annual screening with low dose computerized tomography (LDCT) in those who have had a history of 20 pack years of smoking or more. USPSTF21 LC screening eligibility includes adults ages 50-80 that are current smoker or former smokers that quit within 15 years and have a 20 pack-year history or more of smoking. Exclusion Criteria: * Individuals with pre-established diagnosis of lung cancer. * Participants with current diagnosis of any active malignancy. * Subjects that had undergone lung imaging within previous 3 years. * Pregnant or nursing mothers. * Individuals that received head and neck related treatment less than 5 years before screening. * Individuals with \< 20 pack year history of smoking. * Subjects with previous history of distant metastatic head and neck cancer.

Contact & Investigator

Central Contact

Coral Olazagasti, MD

✉ cxo379@med.miami.edu

📞 305-243-4334

Principal Investigator

Coral Olazagasti, MD

PRINCIPAL INVESTIGATOR

University of Miami

Frequently Asked Questions

Who can join the NCT06124508 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Head and Neck Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06124508 currently recruiting?

Yes, NCT06124508 is actively recruiting participants. Contact the research team at cxo379@med.miami.edu for enrollment information.

Where is the NCT06124508 trial being conducted?

This trial is being conducted at Miami, United States.

Who is sponsoring the NCT06124508 clinical trial?

NCT06124508 is sponsored by University of Miami. The principal investigator is Coral Olazagasti, MD at University of Miami. The trial plans to enroll 44 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology